Figure S1 (GSH) is synthesised in the cytosol and is then slowly transported into mitochondria. Within mitochondria GSH degrades H 2 O 2 and other peroxides by glutathione peroxidases (GPXs) 1 and 4 and the glutathione disulfide (GSSG) generated is recycled by glutathione reductase (GR), driven by the mitochondrial NADPH pool. GSH also recycles oxidised protein thiols in conjunction with glutaredoxin 2 (Grx2) and detoxifies electrophiles and xenobiotics through glutathione S-transferases (GSTs), with the resulting GSH conjugates being exported from mitochondria by ABC transporters. Thioredoxin-2 (Trx2) is a small dithiol protein that maintains other protein dithiols reduced. Doing so converts Trx2(-SH) 2 to its disulfide (Trx2-SS) which is then reduced back to Trx2(-SH) 2 by thioredoxin reductase 2 (TrxR2) driven by the mitochondrial NADPH pool. Trx2 also provides electrons to peroxiredoxin 3 (Prx3) to degrade H 2 O 2 and to methionine sulfoxide reductases (Msr) to reverse methionine oxidation. (b) Reaction of CDNB with GSH catalysed by GSTs to form 1-S-glutathionyl-2,4-dinitrobenzene (GSDNB) and with the active site selenol of TrxR. OMM; outer mitochondrial membrane. IMM; inner mitochondrial membrane. IMS; intermembrane space. gGCL; glutamate cysteine ligase. GS; glutathione synthetase. and MitoCDNB. Rat liver mitochondria (1 mg protein/ml) were incubated with rotenone and succinate, and various concentrations of MitoCDNB for 30 min at 37˚C. Then mitochondria were pelleted and 50 µg protein was separated by SDS-PAGE and analysed by western blot using an anti-Prx3 antibody (1:500) and then re-probed using anti-TPP antiserum (1:1,000), and visualised by ECL. 5 and 6 ) (a) Mice were injected with MitoCDNB (5 mg/kg) and at the indicated times whole kidney or heart tissue were extracted and levels of MitoCDNB, MitoGSDNB and MitoCysDNB quantified by LC-MS/MS. (b) Comparison of mitochondrial GSH levels in in liver, heart and kidney mitochondria isolated from mice that received no injection, or 24 h after injection of vehicle (5 % EtOH) or MitoCDNB (5 mg/kg). Date are means ± SEM, N = 4. The absolute levels of GSH in the mitochondria from the control tissues were: liver = 3.71 ± 0.6; kidney 2.14 ± 0.52; heart 2.36 ± 0.1 (nmol GSH/mg protein). (c) Effect of MitoCDNB on mitochondrial content. C2C12 cells were incubated ± 10 µM MitoCDNB for 4 h and then analysed by western blotting for content of GAPDH and TOM20, which were quantified by Image Studio Lite. The ratio of TOM20 to GAPDH determined and the value in the MitoCDNB sample was normalised to that of the control. Data are means ± SEM of 3 separate incubations. (d) Principal component analysis of effect of MitoCDNB on RNA expression levels. Mice (n = 6 in each condition) were administered MitoCDNB (5 mg/kg) or carrier by tail vein injection and then the liver was isolated 1 and 4 h after injection and the transcriptomes analysed by RNA seq and subjected to principal component analysis using the top 500 most variably expressed genes.
